Terazosin Capsule
Product Images NDC 71335-9607

The text appears to be describing chemical compounds with molecular weights and formulas. The first two lines mention HCl and H2O, which likely indicates an acid solution. The last line provides the molecular weight (MW) of another compound, which is possibly an acid salt. Without more context, it is difficult to determine the purpose or significance of this information.*

The text is a table that shows the Symptom Score and Peak Flow Rate of three studies using Terazosin as a treatment for unknown medical conditions. The table includes the number of patients in each study, the baseline mean, the change percentage of the treatment and the placebo, and the mean of the results. The text also gives additional information about the highest dose shown and the percentage of patients using a certain dose.*

The text describes the results of a study comparing a placebo group to a group receiving Terazosin for the treatment of symptoms and peak flow rate. The study shows a significant increase in both total symptom score and peak flow rate for the Terazosin group compared to the placebo group. Baseline values are given in a table and the study was conducted over a period of three months.*

This is a figure representing a non-placebo controlled study with a sample size of 494, which shows the mean change in total symptom scores from baseline over a period of 30 months. The study indicates that there was a statistically significant improvement in symptom scores compared to the baseline score of 10.7, with an asterisk indicating a p-value of less than 0.05.*

This is a graph showing the mean change in peak flow rate from baseline in a long-term, open-label, non-placebo controlled study involving 494 participants. The x-axis shows the time in months (from 0 to 30) and the y-axis shows the peak flow rate in mL/sec. Different points on the graph show the mean change from baseline at different time points. The graph indicates that there was a statistically significant improvement in peak flow rate compared to baseline.*

This text presents a table showing the mean changes in blood pressure from baseline to the final visit for normotensive and hypertensive patients in all double-bind placebo-controlled studies. The table shows the mean change in SBP (systolic blood pressure) and DBP (diastolic blood pressure) for patients who had DBP less than and greater than 90mmHg. The table compares the mean changes in the Placebo group and Terazosin group. There is a statistical significance marked as p<0.05 against Placebo for Terazosin in hypertensive patients.*

This is a table displaying the adverse reactions that occurred during placebo-controlled trials for the treatment of benign prostatic hyperplasia with terazosin. The table shows the percentage of patients experiencing each adverse reaction in the treatment group (N=636) and the placebo group (N=360). Adverse reactions are grouped by body system, such as body as a whole, cardiovascular system, digestive system, and so on. The adverse reactions reported include asthenia, flu syndrome, hypotension, nausea, dizziness, and impotence, among others. The table also shows statistically significant differences between the treatment and placebo groups (p < 0.05).*

This is a table showing the discontinuation rates of patients during placebo-controlled trials for the treatment of benign prostatic hyperplasia with Terazosin and Placebo. The table lists the percentage of patients and the various body systems with associated symptoms resulting in discontinuation. Symptoms mentioned include headache, postural hypotension, dizziness, blurred vision, and urinary tract infection.*

The text provides a table (Table 3) showing the adverse reactions during placebo-controlled trials of Terazosin for hypertension treatment. The reactions are categorized according to different body systems, including body as a whole, cardiovascular system, digestive system, metabolic and nutritional disorders, musculoskeletal system, nervous system, respiratory system, special senses, and urogenital system. The table shows the percentage of patients who experienced adverse reactions during the trials, with the number of patients in each group (Terazosin and Placebo), and indicates statistically significant reactions at a 0.05 level. Some of the adverse reactions are asthenia, palpitations, blurred vision, and impotence.*

The text provides a table showing the discontinuation rates of patients during placebo-controlled trials for the drug terazosin, which is used to treat hypertension. The table presents the percentage of patients who discontinued the drug due to adverse effects for various body systems, including cardiovascular, digestive, nervous, and respiratory systems, as well as special senses. The adverse effects listed include asthenia, headache, palpitations, postural hypotension, syncope, tachycardia, nausea, peripheral edema, dizziness, paresthesia, somnolence, dyspnea, nasal congestion, and blurred vision.*

This text seems to be a label of a medicine named "Hytrin 10mg Capsule". It is packaged and prepacked by a company called "Buyant Ranch Prepack Bunbank". The label has instructions to store the medicine at room temperature somewhere between 20 to 25 degrees Celsius. The label also contains the NDC number and expiry date.*